Bioresorbable Scaffold Market Report: Trends, Forecast and Competitive Analysis to 2031

Bioresorbable Scaffold Market Trends and Forecast

The future of the global bioresorbable scaffold market looks promising with opportunities in the hospital & clinic and cardiac catheterization laboratory markets. The global bioresorbable scaffold market is expected to grow with a CAGR of 14.5% from 2025 to 2031. The major drivers for this market are the increasing demand for minimally invasive procedures, the rising preference for biocompatible materials, and the growing focus on regenerative medicine.

• Lucintel forecasts that, within the type category, coronary bioabsorbable stent is expected to witness higher growth over the forecast period.

• Within the application category, cardiac catheterization laboratory is expected to witness higher growth.

• In terms of region, APAC is expected to witness the highest growth over the forecast period. Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below.

Emerging Trends in the Bioresorbable Scaffold Market

The bioresorbable scaffold market is experiencing several emerging trends, shaped by technological innovations, clinical advancements, and evolving market needs. Below are five key trends that are reshaping the market:

• Material Advancements: Advances in the materials used for bioresorbable scaffolds, such as poly-L-lactic acid (PLLA) and magnesium alloys, are one of the most significant trends. These materials are being improved to offer better mechanical strength, faster degradation rates, and improved biocompatibility. The ongoing development of new, more durable materials is expected to enhance the performance of bioresorbable scaffolds, making them suitable for a broader range of patients, including those with more severe cases of cardiovascular disease.

• Increased Regulatory Approvals: The bioresorbable scaffold market is benefitting from an increasing number of regulatory approvals, particularly from the FDA in the United States and the PMDA in Japan. As regulatory bodies streamline approval processes and expedite clinical trial timelines for these devices, manufacturers can bring products to market faster. This trend is accelerating the availability of bioresorbable scaffolds, particularly in regions with established healthcare systems like the U.S., Europe, and Japan.

• Integration of Drug-Eluting Features: Bioresorbable scaffolds are increasingly being combined with drug-eluting technology, which helps to prevent restenosis (re-narrowing of the arteries) and improves long-term outcomes. This integration enhances the efficacy of bioresorbable scaffolds, particularly in high-risk patients who have a greater likelihood of restenosis. The ability to deliver localized drug therapy while the scaffold gradually dissolves is making these devices more effective and attractive for cardiovascular interventions.

• Advances in Manufacturing Technologies: With the increasing demand for bioresorbable scaffolds, there has been a push toward advancements in manufacturing technologies, such as 3D printing and advanced polymers. These innovations allow for greater precision, scalability, and customization in the production of bioresorbable scaffolds. The improved manufacturing capabilities are helping companies reduce production costs, improve quality control, and bring down the price of bioresorbable scaffolds, which is essential for making them more accessible in developing markets.

• Shift Toward Minimally Invasive Surgeries: Minimally invasive surgery is a growing trend in the cardiovascular sector, and bioresorbable scaffolds play a key role in this shift. As patient preference for less invasive procedures increases, bioresorbable scaffolds are becoming more common due to their ability to provide support to the arteries without the need for permanent implants. This trend is expected to continue as surgeons and healthcare providers adopt more advanced, less invasive treatment options for heart disease. The bioresorbable scaffold market is evolving rapidly with trends such as material advancements, integration of drug-eluting features, and the rise of minimally invasive surgeries. As manufacturers continue to improve manufacturing processes and the regulatory landscape becomes more favorable, the market is expected to experience significant growth. These trends are driving innovation, making bioresorbable scaffolds an increasingly viable option for treating cardiovascular diseases worldwide.

Recent Development in the Bioresorbable Scaffold Market

Several key developments have been shaping the bioresorbable scaffold market. These developments are expected to influence the future of cardiovascular treatments globally, with more accessible and effective treatment options emerging.

• Development of Magnesium-based Scaffolds: Magnesium-based bioresorbable scaffolds have gained traction in the market due to their favorable mechanical properties and biocompatibility. Companies such as Abbott and Biotronik have been researching magnesium-based scaffolds as they provide an alternative to polymer-based scaffolds, offering better mechanical support and faster resorption. The development of these scaffolds addresses challenges related to scaffold strength, and magnesium’s natural resorption properties make it an attractive option for future coronary interventions.

• Approval of New Drug-Eluting Bioresorbable Scaffolds: A key development in the market has been the approval of new drug-eluting bioresorbable scaffolds. The combination of drug-eluting features with bioresorbable scaffolds aims to reduce the risk of restenosis and improve long-term patient outcomes. Companies like Abbott and Boston Scientific have made significant strides in this area, with new products undergoing clinical trials and receiving regulatory approval in key markets. These developments are increasing the appeal of bioresorbable scaffolds in treating high-risk cardiovascular patients.

• Clinical Trial Successes: Several clinical trials for bioresorbable scaffolds have shown positive results, contributing to increased market confidence. For instance, the ABSORB III trial demonstrated the safety and efficacy of Abbott’s bioresorbable scaffold, leading to wider adoption in clinical practice. These clinical successes are crucial for gaining regulatory approvals and improving the credibility of bioresorbable scaffolds in cardiovascular treatment.

• Breakthroughs in Manufacturing Techniques: Recent advancements in manufacturing techniques, such as additive manufacturing (3D printing) and enhanced polymer coating technologies, are improving the quality and scalability of bioresorbable scaffolds. These innovations allow for greater precision in scaffold construction, better customization for individual patient needs, and more cost-effective production. As manufacturing processes improve, the overall cost of these scaffolds is expected to decline, making them more accessible in emerging markets.

• Global Market Expansion: The bioresorbable scaffold market is expanding beyond traditional markets like the U.S. and Europe, with increasing adoption in emerging markets like India and China. Companies are targeting these regions with cost-effective, locally produced scaffolds to address the growing burden of cardiovascular diseases. As healthcare infrastructure improves and the market matures, bioresorbable scaffolds are poised for broader adoption globally. These key developments, ranging from material innovations to clinical successes and manufacturing breakthroughs, are positively impacting the bioresorbable scaffold market. As technology improves and regulatory bodies continue to support these advancements, bioresorbable scaffolds are expected to play a critical role in the future of cardiovascular care.

Strategic Growth Opportunities in the Bioresorbable Scaffold Market

The bioresorbable scaffold market is expanding rapidly due to advancements in technology, growing cardiovascular disease incidences, and increasing demand for minimally invasive surgical techniques. The ability to develop scaffolds that dissolve safely over time while supporting blood vessels during healing presents significant opportunities for growth in various medical applications. As the market evolves, several strategic growth opportunities are emerging across different applications. These opportunities span key therapeutic areas, including coronary artery disease, peripheral artery disease, and emerging applications in regenerative medicine.

• Coronary Artery Disease: Coronary artery disease (CAD) is one of the most significant applications for bioresorbable scaffolds. These scaffolds are increasingly being adopted for treating CAD due to their ability to provide temporary structural support to arteries without leaving permanent implants. The growth of this application is driven by the rise in heart disease cases worldwide and the increasing demand for non-permanent interventions. With successful clinical trials and regulatory approvals, bioresorbable scaffolds are set to replace traditional metal stents, offering superior patient outcomes with reduced long-term complications.

• Peripheral Artery Disease: Peripheral artery disease (PAD) is another area experiencing growth for bioresorbable scaffolds. PAD, characterized by the narrowing of peripheral arteries, is increasingly being treated with bioresorbable scaffolds due to their potential to support the vascular wall during the healing process without requiring permanent implantation. The need for effective treatment options in PAD is growing as the global prevalence of this condition rises, particularly among older populations. By offering a dissolvable alternative to traditional treatments, bioresorbable scaffolds have the potential to become the treatment of choice for PAD.

• Emerging Use in Regenerative Medicine: Bioresorbable scaffolds are being explored in regenerative medicine as an essential tool for tissue repair and regeneration. In particular, these scaffolds are used for bone and cartilage regeneration, offering support for tissue growth while gradually dissolving to promote healing. This application is still in the early stages but shows significant potential for the future. As research into biocompatible materials advances, bioresorbable scaffolds are likely to play a critical role in tissue engineering and regenerative medicine applications, driving growth in this segment.

• Minimally Invasive Cardiac Surgeries: Minimally invasive cardiac surgeries are gaining traction, and bioresorbable scaffolds play a key role in this transition. These scaffolds help facilitate a less invasive approach to heart surgery, where traditional stents and grafts might be too invasive or inappropriate. The demand for minimally invasive procedures is increasing as patients seek quicker recovery times and less trauma. Bioresorbable scaffolds, which can provide temporary support and dissolve over time, are becoming a preferred option for these procedures, aligning well with the growing trend toward minimally invasive cardiac treatments.

• Penetration in Emerging Economies: Emerging economies such as China, India, and Latin America present significant opportunities for the growth of the bioresorbable scaffold market. As healthcare infrastructure improves and access to advanced treatments increases, the demand for advanced cardiovascular solutions is growing. Bioresorbable scaffolds are seen as a promising solution for regions struggling with a high incidence of cardiovascular diseases and a need for affordable treatment options. Companies are focusing on developing cost-effective scaffolds and enhancing distribution networks in these regions to tap into this large, underserved market. These strategic growth opportunities demonstrate the expanding potential of bioresorbable scaffolds in addressing diverse medical needs. As advancements continue in materials, regulatory approval, and clinical applications, the market for bioresorbable scaffolds is poised for rapid growth. By focusing on coronary artery disease, peripheral artery disease, regenerative medicine, minimally invasive surgeries, and emerging markets, bioresorbable scaffolds will continue to gain prominence in the global healthcare landscape.

Bioresorbable Scaffold Market Driver and Challenges

The bioresorbable scaffold market is influenced by a range of technological, economic, and regulatory drivers, alongside several challenges. These factors impact market growth, adoption, and innovation, driving the trajectory of the industry. Below, we outline the major drivers and challenges, highlighting the factors that will shape the future of the bioresorbable scaffold market. The factors responsible for driving the bioresorbable scaffold market include: 1. Technological Advancements in Materials: Innovations in materials such as poly-L-lactic acid (PLLA) and magnesium alloys are driving the development of bioresorbable scaffolds. The evolution of more biocompatible, durable, and resorbable materials is a key factor in improving the efficacy and safety of these devices. With enhanced mechanical properties and faster resorption rates, the market is seeing an increase in the adoption of bioresorbable scaffolds for coronary artery disease and other applications. These technological advancements are addressing earlier concerns regarding scaffold strength and longevity, encouraging more widespread use. 2. Rising Cardiovascular Disease Incidence: The increasing global burden of cardiovascular diseases (CVD), including coronary artery disease (CAD) and peripheral artery disease (PAD), is one of the primary drivers of the bioresorbable scaffold market. With the aging population and an increase in risk factors such as hypertension and diabetes, demand for advanced treatment options is growing. Bioresorbable scaffolds, which provide a temporary solution without the need for permanent implants, are positioned to address the increasing need for safer and more effective cardiovascular interventions, thus driving market growth. 3. Minimally Invasive Surgical Trends: The rising trend of minimally invasive surgery is another key driver for bioresorbable scaffolds. Patients increasingly prefer less invasive options due to shorter recovery times, reduced complications, and minimal scarring. Bioresorbable scaffolds fit well into this trend as they offer a temporary solution that does not require permanent implantation. As minimally invasive cardiac procedures grow in popularity, bioresorbable scaffolds will continue to gain traction in both coronary and peripheral artery disease treatments. 4. Regulatory Support and Approvals: Government and regulatory support for bioresorbable scaffold development is growing, particularly in regions such as the U.S. and Europe. The FDA and the European Medicines Agency (EMA) have introduced more streamlined processes for the approval of innovative medical devices, which benefits the bioresorbable scaffold market. With successful clinical trials and increasing regulatory approvals, bioresorbable scaffolds are becoming more widely available to patients and healthcare providers, further supporting market expansion. 5. Improved Manufacturing Processes: Advancements in manufacturing technologies, including additive manufacturing (3D printing) and precision engineering, are making it easier to produce bioresorbable scaffolds at scale. These innovations lead to better-quality products, reduced costs, and greater customization for individual patients. As manufacturing processes become more efficient and cost-effective, bioresorbable scaffolds will become more accessible to a wider range of healthcare providers and patients, boosting market growth. Challenges in the bioresorbable scaffold market are: 1. Concerns Over Mechanical Strength: Despite technological advancements, one of the key challenges for bioresorbable scaffolds is ensuring their mechanical strength. Bioresorbable scaffolds must provide adequate support to blood vessels during the healing process, but they must also dissolve at the correct rate to avoid complications. The risk of scaffold collapse, fracture, or delayed resorption continues to pose a challenge for manufacturers. Overcoming this challenge is crucial to increasing market adoption and addressing concerns from both physicians and patients. 2. High Cost of Production: The production of bioresorbable scaffolds remains relatively expensive due to the specialized materials and manufacturing processes involved. This high cost can limit the widespread adoption of these devices, particularly in developing economies where affordability is a key factor. While costs may decrease over time as manufacturing techniques improve, current prices remain a barrier for many healthcare providers and patients, which could slow the market’s expansion. 3. Clinical and Long-Term Efficacy Data: Although bioresorbable scaffolds have shown promise in clinical trials, more long-term data is needed to fully establish their safety and efficacy. The risk of restenosis (re-narrowing of arteries) or other complications in the long term raises concerns for both doctors and patients. Until more robust clinical data are available to demonstrate the long-term effectiveness of these devices, adoption may be slow, particularly among conservative medical practitioners and healthcare providers. The major drivers, including technological advancements, the rise in cardiovascular diseases, and growing regulatory support, are pushing the bioresorbable scaffold market toward rapid growth. However, challenges such as concerns over mechanical strength, high production costs, and the need for more long-term efficacy data must be addressed for the market to achieve its full potential. As these drivers and challenges continue to shape the market, bioresorbable scaffolds are poised to become a key innovation in the treatment of cardiovascular diseases.

List of Bioresorbable Scaffold Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies bioresorbable scaffold companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the bioresorbable scaffold companies profiled in this report include-

• Abbott

• Boston Scientific

• Wego Healthcare

• Elixir

• Arterial Remodeling Technologies

• Lepu Medical

• Huaan Bio

Bioresorbable Scaffold Market by Segment

The study includes a forecast for the global bioresorbable scaffold market by type, application, and region.

Bioresorbable Scaffold Market by Type [Value from 2019 to 2031]:

• Peripheral Bioabsorbable Stents

• Coronary Bioabsorbable Stents

Bioresorbable Scaffold Market by Application [Value from 2019 to 2031]:

• Hospitals & Clinics

• Cardiac Catheterization Laboratory

• Others

Bioresorbable Scaffold Market by Region [Value from 2019 to 2031]:

• North America

• Europe

• Asia Pacific

• The Rest of the World

Country Wise Outlook for the Bioresorbable Scaffold Market

The bioresorbable scaffold market has seen significant advancements in recent years, with innovations in materials, manufacturing techniques, and clinical applications driving growth. Bioresorbable scaffolds (BRS) are being used primarily in the treatment of cardiovascular diseases, where they support blood vessel walls during healing and gradually dissolve over time, eliminating the need for permanent implants. Countries like the United States, China, Germany, India, and Japan are at the forefront of this market, with a focus on enhancing the safety, efficacy, and availability of bioresorbable scaffolds. Below, we discuss the key developments in each country.

• United States: In the United States, advancements in bioresorbable scaffold technology are largely driven by innovation in materials such as poly-L-lactic acid (PLLA) and magnesium alloys. Medical device companies like Abbott and Boston Scientific have been working on developing new bioresorbable coronary scaffolds that reduce long-term complications and enhance patient recovery. Clinical trials and regulatory approvals are moving forward, with the FDA providing a more streamlined approval process for these devices. The market is expected to grow, with a focus on overcoming challenges related to mechanical strength and long-term safety.

• China: China has seen rapid progress in the bioresorbable scaffold market, particularly due to increased government investment in healthcare infrastructure and medical device innovation. Domestic companies are focusing on developing cost-effective bioresorbable scaffolds for the local market, which has seen a rise in cardiovascular diseases. Chinese companies are also improving manufacturing techniques to ensure the production of high-quality scaffolds at scale. While there is still a need for more clinical data, China’s regulatory body has become more open to bioresorbable scaffold trials, which is expected to speed up market adoption.

• Germany: Germany is known for its strong medical technology sector, and the bioresorbable scaffold market is no exception. German companies have been focusing on developing innovative bioresorbable scaffolds with enhanced biocompatibility and mechanical strength. With the country being home to several leading medical device manufacturers, the market has seen considerable investment in research and development. Additionally, Germany’s well-established regulatory environment ensures high safety and efficacy standards. The country is likely to remain a key player in the European bioresorbable scaffold market, particularly as the demand for advanced cardiovascular treatment solutions grows.

• India: India has a rapidly growing medical device market, with increasing adoption of bioresorbable scaffolds in the treatment of cardiovascular diseases. The market in India is primarily driven by the rising incidence of heart diseases and a growing focus on advanced treatment technologies. However, affordability remains a challenge, and there is a need for more cost-effective solutions. Indian companies are working on improving the local manufacturing process for bioresorbable scaffolds, making them more accessible to a wider population. As healthcare spending increases and healthcare access improves, the market is expected to expand.

• Japan: Japan is one of the leading countries in adopting bioresorbable scaffold technology, with a high demand for advanced cardiovascular treatments. Japanese companies have been pioneering the development of bioresorbable scaffolds, particularly in terms of developing magnesium-based materials that dissolve safely in the body. The country’s advanced healthcare system and aging population are driving the demand for minimally invasive cardiovascular treatments. Japan is also at the forefront of clinical trials, and the regulatory body, the Pharmaceuticals and Medical Devices Agency (PMDA), is actively working to fast-track approvals for these innovative devices.

Features of the Global Bioresorbable Scaffold Market

Market Size Estimates: Bioresorbable scaffold market size estimation in terms of value ($B). Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions. Segmentation Analysis: Bioresorbable scaffold market size by type, application, and region in terms of value ($B). Regional Analysis: Bioresorbable scaffold market breakdown by North America, Europe, Asia Pacific, and Rest of the World. Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the bioresorbable scaffold market. Strategic Analysis: This includes M&A, new product development, and competitive landscape of the bioresorbable scaffold market. Analysis of competitive intensity of the industry based on Porter’s Five Forces model.

FAQ

Q1. What is the growth forecast for bioresorbable scaffold market? Answer: The global bioresorbable scaffold market is expected to grow with a CAGR of 14.5% from 2025 to 2031. Q2. What are the major drivers influencing the growth of the bioresorbable scaffold market? Answer: The major drivers for this market are the increasing demand for minimally invasive procedures, the rising preference for biocompatible materials, and the growing focus on regenerative medicine. Q3. What are the major segments for bioresorbable scaffold market? Answer: The future of the bioresorbable scaffold market looks promising with opportunities in the hospital & clinic and cardiac catheterization laboratory markets. Q4. Who are the key bioresorbable scaffold market companies? Answer: Some of the key bioresorbable scaffold companies are as follows:

• Abbott

• Boston Scientific

• Wego Healthcare

• Elixir

• Arterial Remodeling Technologies

• Lepu Medical

• Huaan Bio Q5. Which bioresorbable scaffold market segment will be the largest in future? Answer: Lucintel forecasts that, within the type category, coronary bioabsorbable stent is expected to witness higher growth over the forecast period. Q6. In bioresorbable scaffold market, which region is expected to be the largest in next 5 years? Answer: In terms of region, APAC is expected to witness the highest growth over the forecast period. Q7. Do we receive customization in this report? Answer: Yes, Lucintel provides 10% customization without any additional cost.